Abstract Bictegravir (BIC), a second-generation integrase strand-transfer inhibitor (INSTI)
with high resilience to INSTI-resistance mutations, is integrated as a key component of …

The antiretroviral treatment gap between adults and children persists. The potential benefits
from rollout of new paediatric DTG-based fixed-dose combination ART for first-line treatment …

Current Opinion in HIV and AIDS Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Background Child-friendly fixed-dose combination (FDC) antiretroviral therapy (ART)
options are limited. We evaluated the pharmacokinetics, safety, and tolerability of dispersible …

Background Children living with human immunodeficiency virus (HIV, CLWH) are at high
risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART). We …

Tuberculosis (TB) is the leading cause of death from a single infectious agent. The burden is
highest in some low-and middle-income countries. One-quarter of the world's population is …

Background We evaluated dolutegravir pharmacokinetics in infants with human
immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based …

Background Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse
transcriptase inhibitors, is currently the preferred first-line treatment for human …

Abstract Treatment options for children living with HIV have historically been less effective,
less practical and more difficult to implement compared with those for adults, as the research …

Increasing HIV drug resistance is an important public health concern. The current study
aimed to assess HIV drug resistance among people who live with HIV (PLWH) experiencing …